CLDI
Calidi Biotherapeutics, Inc.Company Information
- Company Name
- Calidi Biotherapeutics, Inc.
- CIK
- CIK0001855485
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CLDI: NYSE, CLDWW: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CLDI
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-21
- Last sale
- 2025-12-12
- Shares purchased (TTM)
- 227,500
- Shares sold (TTM)
- 10,850
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 525,596
- Shares outstanding
- 1,416,000
- Ownership
- 37.12%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -10.06%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | 4 | 7 | 6 | 10 | 5 | 11 | 10 | 2 | 1 | 1 | 2 | 10 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 5 | 7 | 6 | 11 | 6 | 11 | 10 | 2 | 2 | 2 | 4 | 12 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Machinery And Equipment Gross | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Derivative Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Assets | 7 | 10 | 9 | 14 | 9 | 15 | 14 | 7 | 6 | 7 | 10 | 19 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 3 | 4 | 4 | 5 | 5 | 5 | 9 | 12 | 13 | 15 | 10 | 11 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | 1 | - | - | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes And Loans | - | - | - | - | - | - | - | - | - | - | 2 | 2 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | - | 2 | 2 | 3 | - | - | ||||||
| Liabilities | 4 | 5 | 5 | 7 | 7 | 8 | 12 | 16 | 18 | 22 | 18 | 20 | ||||||
| Common Stock Value | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 2 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 153 | 151 | 145 | 144 | 134 | 134 | 123 | 107 | 101 | 92 | 91 | 90 | ||||||
| Stockholders Equity | 3 | 5 | 4 | 7 | 2 | 7 | 2 | -10 | -12 | -15 | -8 | -1 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -150 | -146 | -142 | -138 | -132 | -127 | -122 | -118 | -113 | -107 | -100 | -91 | ||||||
Temporary Equity | ||||||||||||||||||
| Minority Interest | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Liabilities And Stockholders Equity | 7 | 10 | 9 | 14 | 9 | 15 | 14 | 7 | 6 | 7 | 10 | 19 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 330 | 330 | 330 | 330 | 330 | 330 | 330 | 330 | 330 | 330 | 330 | 330 | ||||||
| Common Stock Shares Issued | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCalidi Biotherapeutics, Inc. (CLDI) — SEC Financial Statements & Analysis
Calidi Biotherapeutics, Inc. (CLDI) is a biological products, (no diagnostic substances) company, incorporated in DE. Calidi Biotherapeutics, Inc. trades on NYSE, OTC as: CLDI, CLDWW. Calidi Biotherapeutics, Inc. (CLDI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Calidi Biotherapeutics, Inc. carries a market cap of $3.85M, a P/E ratio of -0.16x, a P/B ratio of 1.23x, an enterprise value of $-110.48K, and an EV/EBITDA multiple of 0.01x. On profitability, it posts a Return on Equity (ROE) of -897.64% and a Return on Assets (ROA) of -282.44%. Per share, it reports EPS of $-16.51, diluted EPS of $-16.51, free cash flow per share of $-12.54, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 17.32% year-over-year, and EPS growth of -85.09% year-over-year. On the balance sheet, it maintains a current ratio of 1.68x, a quick ratio of 1.26x, working capital of $2.19M, a debt-to-equity ratio of 1.30x, a debt ratio of 0.57, an interest coverage ratio of -137.32x, free cash flow of $-17.75M (TTM), and net debt of $-3.96M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.85M
- P/E TTM
- -0.16x
- EPS TTM
- $-16.51
- P/B TTM
- 1.23x
- ROE TTM
- -897.64%
- ROA TTM
- -282.44%
- Debt To Equity
- 1.30x
- Free Cash Flow TTM
- $-17.75M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Calidi Biotherapeutics, Inc. in?
Calidi Biotherapeutics, Inc. (CLDI) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CLDI trade on?
Calidi Biotherapeutics, Inc. (CLDI) trades on the NYSE, OTC.
Where is Calidi Biotherapeutics, Inc. incorporated?
Calidi Biotherapeutics, Inc. is incorporated in DE.
When was Calidi Biotherapeutics, Inc. (CLDI)'s most recent SEC filing?
Calidi Biotherapeutics, Inc. (CLDI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CLDI's market cap?
Calidi Biotherapeutics, Inc. (CLDI) has a market capitalization of $3.85M as of 2026-06-30.
What is CLDI's EPS (earnings per share)?
Calidi Biotherapeutics, Inc. (CLDI)'s trailing twelve month EPS is $-16.51 as of 2026-06-30.
What is CLDI's ROE (return on equity)?
Calidi Biotherapeutics, Inc. (CLDI)'s trailing twelve month Return on Equity (ROE) is -897.64% as of 2026-06-30.
What is CLDI's ROA (return on assets)?
Calidi Biotherapeutics, Inc. (CLDI)'s trailing twelve month Return on Assets (ROA) is -282.44% as of 2026-06-30.
What is CLDI's EV/EBITDA?
Calidi Biotherapeutics, Inc. (CLDI)'s trailing twelve month EV/EBITDA is 0.01x as of 2026-06-30.